ReviewCurrent opinion in oncology2016
New and emerging developments in extensive-stage small cell lung cancer therapeutics.
Review in Current opinion in oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Significance of CD8+T cells related gene ITGB2 in prognosis and tumor microenvironment of small cell lung cancer.Medicine · 2025Article
- Castasterone, a Plant Steroid Hormone, Affects Human Small-Cell Lung Cancer Cells and Reverses Multi-Drug Resistance.Pharmaceuticals (Basel, Switzerland) · 2023Article
- The mechanism and application of traditional Chinese medicine extracts in the treatment of lung cancer and other lung-related diseases.Frontiers in pharmacology · 2023Review
- Chinese Medicine Treatment Prolonged Survival in Small Cell Lung Cancer Patients: A Clinical Observation.Chinese journal of integrative medicine · 2021Article
- Prophylactic cranial irradiation in patients with small cell lung cancer in The Netherlands: A population-based study.Clinical and translational radiation oncology · 2021Article
- Role of thoracic radiotherapy in extensive stage small cell lung cancer: a systemic review and meta-analysis.Annals of translational medicine · 2021Article
- Bioactive Compounds from Marine Heterobranchs.Marine drugs · 2020Review
- Review
- Editorial for "Longitudinal cell-free DNA analysis in patients with small cell lung cancer reveals dynamic insights into treatment efficacy and disease relapse".Translational lung cancer research · 2018Article
- Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer.Thoracic cancer · 2018Article
- A Curated Target Gene Pool Assisting Early Disease Prediction and Patient-Specific Treatment for Small Cell Lung Cancer.Journal of computational biology : a journal of computational molecular cell biology · 2018Article
- Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy.Lung cancer (Amsterdam, Netherlands) · 2018Article
- Marine Mollusk-Derived Agents with Antiproliferative Activity as Promising Anticancer Agents to Overcome Chemotherapy Resistance.Medicinal research reviews · 2017Review
- Timing of thoracic radiotherapy in the treatment of extensive-stage small-cell lung cancer: important or not?Radiation oncology (London, England) · 2017Article
- MicroRNA-451 sensitizes lung cancer cells to cisplatin through regulation of Mcl-1.Molecular and cellular biochemistry · 2016Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewExtensive-stage small cell lung cancer (ES-SCLC) remains a disease with a dismal prognosis, with median survival of approximately 8-10 months. Despite many attempts to develop effective systemic therapies, very little progress has been made in the last several decades. Platinum-based combination chemotherapy remains the standard of care in the first-line setting and is associated with high response rates albeit short-lived. However, there have been recent advances in the use of radiation therapy, as well as new insights into the biology of SCLC. RECENT
findingsSome of the most appreciable advances in the last decade have involved the use of local radiation therapy. With the use of new laboratory techniques such as genomic sequencing, there remains promise of rationally targeted drug development. Circulating tumor cell research may also provide insights to SCLC biology and further refine treatment. SUMMARY: Systemic therapy for SCLC has changed little over the past 30 years with the most significant advances in ES-SCLC relating to radiotherapy rather than systemic therapy. The effectiveness of prophylactic cranial irradiation and thoracic radiotherapy has renewed interest in therapeutics focused on the modulation of DNA damage or repair. Recent developments in genomic sequencing and immunotherapy may translate to new treatment paradigms for SCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.